Notice: This company has been marked as potentially delisted and may not be actively trading. Intercept Pharmaceuticals (ICPT) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Intercept’s liver disease drug Ocaliva faces FDA approval delayOctober 19, 2024 | msn.comIntercept Provides Regulatory Update Regarding sNDA for OCALIVAOctober 17, 2024 | finance.yahoo.comFDA advisers vote against confirmatory data for Intercept's liver disease drugSeptember 13, 2024 | reuters.comFDA staff raises efficacy concerns over Intercept's liver disease drugSeptember 11, 2024 | reuters.comFindings From COBALT Trial, Including External Control Arm, Published in The American Journal of GastroenterologySeptember 6, 2024 | finance.yahoo.comIntercept Announces New Data to be Presented at the European Association for the Study of the Liver (EASL) Congress 2024May 29, 2024 | finance.yahoo.com89bio gains 47% on topline data for NASH candidateMarch 21, 2024 | msn.comIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCFebruary 29, 2024 | globenewswire.comIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023November 13, 2023 | finance.yahoo.comIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comTrading was temporarily halted for "ICPT" at 07:11 PM with a stated reason of "News pending."November 8, 2023 | marketbeat.comAlfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.November 8, 2023 | finance.yahoo.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38November 2, 2023 | msn.comWill Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowOctober 31, 2023 | finance.yahoo.comStocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOctober 27, 2023 | finance.yahoo.comIntercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoOctober 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17October 5, 2023 | msn.comIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saySeptember 28, 2023 | msn.comCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)September 28, 2023 | msn.comRoyal Bank of Canada Increases Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target to $19.00Royal Bank of Canada boosted their price objective on shares of Intercept Pharmaceuticals from $12.00 to $19.00 in a research note on Wednesday.September 27, 2023 | marketbeat.comIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value AssessmentSeptember 27, 2023 | markets.businessinsider.comIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealSeptember 27, 2023 | proactiveinvestors.comCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"September 26, 2023 | msn.comShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with AlfasigmaSeptember 26, 2023 | benzinga.comIntercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All PartiesSeptember 26, 2023 | seekingalpha.comWhy Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?September 26, 2023 | investorplace.comIntercept Pharma Shares Surge Toward Alfasigma Acquisition PriceSeptember 26, 2023 | marketwatch.comIntercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premiumSeptember 26, 2023 | msn.comItaly's Alfasigma to buy drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | reuters.comAlfasigma To Acquire Intercept Pharma Fo $19 Per Share In CashSeptember 26, 2023 | markets.businessinsider.comWhy Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?September 26, 2023 | markets.businessinsider.comAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | finance.yahoo.comTrading was temporarily halted for "ICPT" at 07:09 AM with a stated reason of "News pending."September 26, 2023 | marketbeat.comFY2025 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Lifted by Zacks ResearchIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) - Analysts at Zacks Research boosted their FY2025 earnings per share (EPS) estimates for Intercept Pharmaceuticals in a report issued on Monday, September 18th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical cSeptember 20, 2023 | marketbeat.comIntercept Pharma (ICPT) Receives a Hold from RBC CapitalSeptember 9, 2023 | markets.businessinsider.comWhy CymaBay Therapeutics Stock Is Jumping TodaySeptember 8, 2023 | finance.yahoo.comWhy Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?September 7, 2023 | finance.yahoo.comCredit Suisse AG Has $1.71 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Credit Suisse AG lowered its holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) by 13.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 126,963 shares of the biopharmaceutical company's stock after selSeptember 6, 2023 | marketbeat.comExodusPoint Capital Management LP Has $1.04 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)ExodusPoint Capital Management LP trimmed its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) by 85.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,558 shares of the biopharmaceutical cSeptember 5, 2023 | marketbeat.comWhy Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?September 1, 2023 | finance.yahoo.comLeerink Partnrs Equities Analysts Lift Earnings Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) - Equities research analysts at Leerink Partnrs raised their Q4 2023 EPS estimates for Intercept Pharmaceuticals in a report issued on Thursday, August 24th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical companyAugust 28, 2023 | marketbeat.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Acquired by Pictet Asset Management SAPictet Asset Management SA lifted its holdings in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) by 181.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 694,637 shares of the biopharmaceutical comAugust 23, 2023 | marketbeat.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Bought by Mirae Asset Global Investments Co. Ltd.Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) by 82.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investAugust 22, 2023 | marketbeat.comQ3 2023 Earnings Forecast for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Issued By Zacks ResearchIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) - Stock analysts at Zacks Research cut their Q3 2023 earnings per share (EPS) estimates for shares of Intercept Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 16th. Zacks Research analyst E. BagAugust 21, 2023 | marketbeat.comZacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) - Analysts at Zacks Research raised their Q2 2024 EPS estimates for shares of Intercept Pharmaceuticals in a research note issued to investors on Wednesday, August 16th. Zacks Research analyst E. Bagri now anticipates that the biopharmacAugust 18, 2023 | marketbeat.comIntercept Pharmaceuticals (NASDAQ:ICPT) Downgraded to Hold at StockNews.comStockNews.com lowered shares of Intercept Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday.August 11, 2023 | marketbeat.comB. Riley Weighs in on Intercept Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT - Free Report) - B. Riley issued their FY2025 earnings estimates for Intercept Pharmaceuticals in a research note issued to investors on Thursday, August 3rd. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earningsAugust 7, 2023 | marketbeat.comCanaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Buy RecommendationAugust 4, 2023 | msn.comIntercept: Narrowed Market, Concentrated Strategy (Rating Upgrade)August 3, 2023 | seekingalpha.com Get Intercept Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ICPT Media Mentions By Week ICPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ICPT News Sentiment▼0.300.45▲Average Medical News Sentiment ICPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ICPT Articles This Week▼00▲ICPT Articles Average Week Get Intercept Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ENTA News Today GERN News Today MYGN News Today LGND News Today CLDX News Today MNKD News Today BCRX News Today DVAX News Today NVAX News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ICPT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intercept Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
